Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3859-3866

  Gasparri, Anna Maria ^a   Jachetti, Elena ^a   Colombo, Barbara ^a   Sacchi, Angelina ^a   Curnis, Flavio ^a   Rizzardi, Gian Paolo ^b   Traversari, Catia ^b   Bellone, Matteo ^a   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; MELPHALAN; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; FIBROSARCOMA; IN VITRO STUDY; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; T LYMPHOCYTE; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRYPTOPHAN;

EID: 57749115015     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0538     Document Type: Article

References (49)

1. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
2. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH. Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res 1987;47:2563-70.
3. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86.
4. Dobrzanski MJ, Reome JB, Dutton RW. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin Immunol 2001;98:70-84.
5. Bancroft GJ, Schreiber RD, Bosma GC, Bosma MJ, Unanue ER. A T cell-independent mechanism of macrophage activation by interferon-γ. J Immunol 1987;139:1104-7.
6. Schreiber RD, Hicks LJ, Celada A, Buchmeier NA, Gray PW. Monoclonal antibodies to murine γ-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol 1985;134:1609-18.
7. Liew FY, Li Y, Millott S. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990;145:4306-10.
8. Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
9. Basham TY, Merigan TC. Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol 1983;130:1492-4.
10. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant γ interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. J Interf Res 1985;5:23-32.
11. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
12. Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation; differences among T-cell subsets. Immunol Rev 1989;111:79-110.
13. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
14. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001;194:1549-60.
15. Blankenstein T, Qin Z. The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 2003;15:148-54.
16. Foon KA, Sherwin SA, Abrams PG, et al. A phase I trial of recombinant γ interferon in patients with cancer. Cancer Immunol Immunother 1985;20:193-7.
17. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. Phase II studies of recombinant human interferon g in metastatic renal cell carcinoma. J Biol Resp Mod 1987;6:20-7.
18. Kurzrock R, Rosenblum MG, Sherw in SA, et al. Pharmacokinetics, single-dose tolerance,and biological activity of recombinant γ-interferon in cancer patients. Cancer Res 1985;45:2866-72.
19. Talmadge JE, Black PL, Tribble H, et al. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFNγ, and rH IL-2. Drugs Exp Clin Res 1987;13:327-37.
20. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant γ-interferon. Cancer Res 1986;46:5401-5.
21. Aulitzky W, Gastl G, Aulitzky WE, et al. Interferon-γ for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of β-2 microglobulin and neopterin responses. Immunobiol 1987;176:85-95.
22. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFN-γ to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 2005;65:2906-13.
23. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
24. Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62:867-74.
25. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
26. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-73.
27. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3.
28. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
29. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-59.
30. Moro M, Pelagi M, Fulci G, et al. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor α. Cancer Res 1997;57:1922-8.
31. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
32. Gasparri A, Moro M, Curnis F, et al. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor α in mouse models. Cancer Res 1999;59:2917-23.
33. Kudo Y, Boyd CA, Sargent IL, Redman CW. Modulation of indoleamine 2,3-dioxygenase by interferon-γ in human placental chorionic villi. Mol Hum Reprod 2000;6:369-74.
34. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
35. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
36. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
37. Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Arch Biochem Biophys 1980;203:343-51.
38. Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolylamine 2,3-dioxygenase. Its tissue distribution and characterization of the placental enzyme. Biochem J 1985;230:635-8.
39. Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 1986;261:3648-53.
40. Taylor MW, Feng GS. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516-22.
41. Wood KJ, Sawitzki B. Interferon γ: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 2006;27:183-7.
42. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1069-77.
43. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. 5J Exp Med 2002;196:459-68.
44. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196:447-57.
45. + T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol 2006;36:296-304.
46. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant 2006;6:1320-30.
47. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008;112:2628-35.
48. Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005;9:831-49.
49. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7.